{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:23:02Z","timestamp":1790799782302,"version":"4.1.0"},"reference-count":244,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.hoc.2020.08.010","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T09:21:15Z","timestamp":1603704075000},"page":"29-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Biology of Melanoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Stephen M.","family":"Ostrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/icb\/6.1.43","article-title":"Genetic variations in the fine structure and ontogeny of mouse melanin granules","volume":"6","author":"Moyer","year":"1966","journal-title":"Am Zool"},{"key":"10.1016\/j.hoc.2020.08.010_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2014.02.003","article-title":"Melanosome transfer: it is best to give and receive","volume":"29","author":"Wu","year":"2014","journal-title":"Curr Opin Cell Biol"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib3","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1083\/jcb.143.7.1899","article-title":"Visualization of melanosome dynamics within wild-type and dilute melanocytes suggests a paradigm for myosin V function In\u00a0vivo","volume":"143","author":"Wu","year":"1998","journal-title":"J\u00a0Cell Biol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/jid.1953.114","article-title":"Comparison of skin color with melanin content","volume":"21","author":"Gates","year":"1953","journal-title":"J\u00a0Invest Dermatol"},{"issue":"R1","key":"10.1016\/j.hoc.2020.08.010_bib5","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/hmg\/ddp003","article-title":"Molecular genetics of human pigmentation diversity","volume":"18","author":"Sturm","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/1523-1747.ep12521344","article-title":"Recent advances in the chemistry of melanogenesis in mammals","volume":"75","author":"Prota","year":"1980","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0092-8674(93)90572-8","article-title":"Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function","volume":"72","author":"Robbins","year":"1993","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.cell.2006.12.045","article-title":"Central role of p53 in the suntan response and pathologic hyperpigmentation","volume":"128","author":"Cui","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2230.2006.02128.x","article-title":"Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors","volume":"31","author":"Millington","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2020.08.010_bib10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.celrep.2017.05.042","article-title":"A\u00a0UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin","volume":"19","author":"Mujahid","year":"2017","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1755-148X.2010.00760.x","article-title":"Downregulation of SIK2 expression promotes the melanogenic program in mice","volume":"23","author":"Horike","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/0008-5472.CAN-03-2440","article-title":"Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma","volume":"64","author":"Miller","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9440(10)63657-7","article-title":"MLANA\/MART1 and SILV\/PMEL17\/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma","volume":"163","author":"Du","year":"2003","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2020.08.010_bib14","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1073\/pnas.1205575110","article-title":"BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition","volume":"110","author":"Haq","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0092-8674(02)00762-6","article-title":"Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability","volume":"109","author":"McGill","year":"2002","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2004.10.014","article-title":"Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF","volume":"6","author":"Du","year":"2004","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0092-8674(93)90429-T","article-title":"Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein","volume":"74","author":"Hodgkinson","year":"1993","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ng0894-509","article-title":"A\u00a0gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1","volume":"7","author":"Hughes","year":"1994","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccr.2006.04.021","article-title":"Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers","volume":"9","author":"Davis","year":"2006","journal-title":"Cancer Cell"},{"issue":"7047","key":"10.1016\/j.hoc.2020.08.010_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"issue":"7375","key":"10.1016\/j.hoc.2020.08.010_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10630","article-title":"A\u00a0novel recurrent mutation in MITF predisposes to familial and sporadic melanoma","volume":"480","author":"Yokoyama","year":"2011","journal-title":"Nature"},{"issue":"7375","key":"10.1016\/j.hoc.2020.08.010_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A\u00a0SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1195-328","article-title":"Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans","volume":"11","author":"Valverde","year":"1995","journal-title":"Nat Genet"},{"issue":"Suppl 8","key":"10.1016\/j.hoc.2020.08.010_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1600-0749.13.s8.28.x","article-title":"The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation","volume":"13 Suppl 8","author":"Abdel-Malek","year":"2000","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.hoc.2020.08.010_bib26","doi-asserted-by":"crossref","first-page":"12064","DOI":"10.1038\/ncomms12064","article-title":"Germline MC1R status influences somatic mutation burden in melanoma","volume":"7","author":"Robles-Espinoza","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib27","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/hmg\/5.10.1663","article-title":"The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma","volume":"5","author":"Valverde","year":"1996","journal-title":"Hum Mol Genet"},{"issue":"7109","key":"10.1016\/j.hoc.2020.08.010_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature05098","article-title":"Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning","volume":"443","author":"D'Orazio","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1086\/302711","article-title":"Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?","volume":"66","author":"Nobuhisa","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2016.0050","article-title":"Human determinants and the role of melanocortin-1 receptor variants in melanoma risk independent of UV radiation exposure","volume":"152","author":"Wendt","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jamadermatol.2016.0524","article-title":"Red Hair, Light Skin, and UV-Independent Risk for Melanoma Development in Humans","volume":"152","author":"Roider","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7424","key":"10.1016\/j.hoc.2020.08.010_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair\/fair skin background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/pcmr.12262","article-title":"Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma","volume":"27","author":"Napolitano","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7051","key":"10.1016\/j.hoc.2020.08.010_bib34","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040546","article-title":"Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi","volume":"11","author":"Jansen","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2012.05.043","article-title":"New recommendations for the categorization of cutaneous features of congenital melanocytic nevi","volume":"68","author":"Krengel","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib38","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jid.2018.07.045","article-title":"Genetic abnormalities in large to giant congenital nevi: beyond NRAS mutations","volume":"139","author":"Martins da Silva","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib39","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjd.18106","article-title":"Does the gene matter? Genotype-phenotype and genotype-outcome associations in congenital melanocytic naevi","volume":"182","author":"Polubothu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib40","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/bjd.15301","article-title":"Melanoma in congenital melanocytic naevi","volume":"176","author":"Kinsler","year":"2017","journal-title":"Br J Dermatol"},{"issue":"56","key":"10.1016\/j.hoc.2020.08.010_bib41","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1038\/onc.2008.323","article-title":"Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence","volume":"27","author":"Leikam","year":"2008","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib42","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jid.2018.12.033","article-title":"Molecular genomic profiling of melanocytic nevi","volume":"139","author":"Colebatch","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib43","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.jid.2018.02.012","article-title":"Whole-exome sequencing of acquired nevi identifies mechanisms for development and maintenance of benign neoplasms","volume":"138","author":"Stark","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jid.2016.11.017","article-title":"Genomic characterization of dysplastic nevi unveils implications for diagnosis of melanoma","volume":"137","author":"Melamed","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/archderm.139.3.282","article-title":"The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate","volume":"139","author":"Tsao","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccell.2018.06.005","article-title":"Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution","volume":"34","author":"Shain","year":"2018","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.hoc.2020.08.010_bib47","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib48","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archderm.139.12.1620","article-title":"Cutaneous melanomas associated with nevi","volume":"139","author":"Bevona","year":"2003","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib49","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaad.2014.08.025","article-title":"The utility of re-excising mildly and moderately dysplastic nevi: a retrospective analysis","volume":"71","author":"Strazzula","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib50","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib51","first-page":"83","article-title":"The developmental biology of primary human malignant melanomas","volume":"2","author":"Clark","year":"1975","journal-title":"Semin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib52","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CMR.0b013e32836410fe","article-title":"Characteristics and survival of patients with invasive amelanotic melanoma in the USA","volume":"23","author":"Moreau","year":"2013","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamadermatol.2014.1348","article-title":"Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study","volume":"150","author":"Thomas","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib55","first-page":"130","article-title":"Early detection of malignant melanoma: the role of physician examination and self-examination of the skin","volume":"35","author":"Friedman","year":"1985","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/archdermatol.2011.264","article-title":"The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007","volume":"148","author":"Shaikh","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib57","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaad.2012.09.047","article-title":"Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia","volume":"68","author":"Mar","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2133.1987.tb05843.x","article-title":"The risk of progression of lentigo maligna to lentigo maligna melanoma","volume":"116","author":"Weinstock","year":"1987","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib59","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Whiteman","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib60","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/(SICI)1097-0215(19980911)77:6<843::AID-IJC8>3.0.CO;2-U","article-title":"p53 expression and risk factors for cutaneous melanoma: a case-control study","volume":"77","author":"Whiteman","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2020.08.010_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"issue":"19","key":"10.1016\/j.hoc.2020.08.010_bib62","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.2006.06.1325","article-title":"Anatomic site, sun exposure, and risk of cutaneous melanoma","volume":"24","author":"Whiteman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib63","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1055-9965.EPI-10-0233","article-title":"Melanocytic nevi, nevus genes, and melanoma risk in a large case-control study in the United Kingdom","volume":"19","author":"Newton-Bishop","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib64","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ijc.24011","article-title":"Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis","volume":"124","author":"Olsen","year":"2009","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jid.2015.12.035","article-title":"Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas","volume":"136","author":"Hacker","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"17","key":"10.1016\/j.hoc.2020.08.010_bib66","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","article-title":"BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage","volume":"19","author":"Mar","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.hoc.2020.08.010_bib67","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/pcmr.12851","article-title":"Tumor genetic heterogeneity analysis of chronic sun-damaged melanoma","volume":"33","author":"Sanna","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.hoc.2020.08.010_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-016-2747-6","article-title":"Racial differences in six major subtypes of melanoma: descriptive epidemiology","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib71","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2020.08.010_bib72","article-title":"Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease","author":"Basurto-Lozada","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib73","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jid.2019.12.031","article-title":"Integrating next-generation sequencing with morphology improves prognostic and biologic classification of spitz neoplasms","volume":"140","author":"Quan","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2020.08.010_bib74","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib75","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/ng.3382","article-title":"Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway","volume":"47","author":"Shain","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib76","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.03.066","article-title":"Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma","volume":"81","author":"DeWane","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7688","key":"10.1016\/j.hoc.2020.08.010_bib77","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature25187","article-title":"High response rate to PD-1 blockade in desmoplastic melanomas","volume":"553","author":"Eroglu","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.hoc.2020.08.010_bib79","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic Therapy for Melanoma: ASCO Guideline","author":"Seth","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib80","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jso.25302","article-title":"Melanoma of unknown primary","volume":"119","author":"Song","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib81","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/pcmr.12153","article-title":"Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma","volume":"26","author":"Dutton-Regester","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib82","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/jid.2009.48","article-title":"A\u00a0population-based study of Australian twins with melanoma suggests a strong genetic contribution to liability","volume":"129","author":"Shekar","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/ng0196-97","article-title":"Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma","volume":"12","author":"Zuo","year":"1996","journal-title":"Nat Genet"},{"issue":"16","key":"10.1016\/j.hoc.2020.08.010_bib84","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1073\/pnas.93.16.8541","article-title":"Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population","volume":"93","author":"FitzGerald","year":"1996","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"6531","key":"10.1016\/j.hoc.2020.08.010_bib85","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/375506a0","article-title":"Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition","volume":"375","author":"Koh","year":"1995","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib86","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/ng.2941","article-title":"Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma","volume":"46","author":"Shi","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib87","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.2947","article-title":"POT1 loss-of-function variants predispose to familial melanoma","volume":"46","author":"Robles-Espinoza","year":"2014","journal-title":"Nat Genet"},{"issue":"6122","key":"10.1016\/j.hoc.2020.08.010_bib88","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib89","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju408","article-title":"Nonsense mutations in the shelterin complex genes ACD and TERF2IP in familial melanoma","volume":"107","author":"Aoude","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2020.08.010_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-020-0611-8","article-title":"Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility","author":"Landi","year":"2020","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib91","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ng.3373","article-title":"Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma","volume":"47","author":"Law","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib92","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3927","article-title":"A\u00a0common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF","volume":"49","author":"Choi","year":"2017","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib93","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41467-020-14594-5","article-title":"Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma","volume":"11","author":"Sarin","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib94","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ng.410","article-title":"Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi","volume":"41","author":"Falchi","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib95","doi-asserted-by":"crossref","first-page":"36.e10","DOI":"10.1016\/j.jaad.2018.02.052","article-title":"Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort","volume":"79","author":"Cho","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib97","first-page":"69","article-title":"Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies","volume":"12","author":"Whiteman","year":"2001","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.hoc.2020.08.010_bib98","doi-asserted-by":"crossref","first-page":"e4757","DOI":"10.1136\/bmj.e4757","article-title":"Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis","volume":"345","author":"Boniol","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/php.12377","article-title":"UV signature mutations","volume":"91","author":"Brash","year":"2015","journal-title":"Photochem Photobiol"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib100","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/sj.jid.5700458","article-title":"Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?","volume":"126","author":"Thomas","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2020.08.010_bib101","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0076-6879(00)19035-4","article-title":"Photocarcinogenesis: Photocarcinogenesis: UVA vs UVB","volume":"319","author":"de Gruijl","year":"2000","journal-title":"Meth Enzymol"},{"issue":"7510","key":"10.1016\/j.hoc.2020.08.010_bib102","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nature13298","article-title":"Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53","volume":"511","author":"Viros","year":"2014","journal-title":"Nature"},{"issue":"7331","key":"10.1016\/j.hoc.2020.08.010_bib103","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09666","article-title":"Interferon-\u03b3 links ultraviolet radiation to melanomagenesis in mice","volume":"469","author":"Zaidi","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib104","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/jid.2013.9","article-title":"UVB-induced melanocyte proliferation in neonatal mice driven by CCR2-independent recruitment of Ly6c(low)MHCII(hi) macrophages","volume":"133","author":"Handoko","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2020.08.010_bib105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-1-62703-727-3_15","article-title":"Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma","volume":"1102","author":"Xu","year":"2014","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib106","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib107","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92102","article-title":"Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation","volume":"2","author":"Badal","year":"2017","journal-title":"JCI Insight"},{"issue":"47","key":"10.1016\/j.hoc.2020.08.010_bib108","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1038\/s41388-018-0385-y","article-title":"RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas","volume":"37","author":"Kunz","year":"2018","journal-title":"Oncogene"},{"issue":"13","key":"10.1016\/j.hoc.2020.08.010_bib109","doi-asserted-by":"crossref","first-page":"11683","DOI":"10.18632\/oncotarget.3549","article-title":"Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort","volume":"6","author":"Nsengimana","year":"2015","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.hoc.2020.08.010_bib110","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.1158\/1078-0432.CCR-18-3659","article-title":"Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma","volume":"25","author":"Thakur","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib111","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2020.03.053","article-title":"Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients","volume":"83","author":"Greenhaw","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1755-148X.2010.00732.x","article-title":"Loss of nuclear receptor RXR\u03b1 in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas","volume":"23","author":"Hyter","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib113","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1186\/s12885-017-3714-6","article-title":"Ablation of epidermal RXR\u03b1 in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas","volume":"17","author":"Chagani","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib114","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/jid.2010.290","article-title":"RXR\u03b1 ablation in epidermal keratinocytes enhances UVR-induced DNA damage, apoptosis, and proliferation of keratinocytes and melanocytes","volume":"131","author":"Wang","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/pcmr.12826","article-title":"Keratinocyte cadherin desmoglein 1 controls melanocyte behavior through paracrine signaling","volume":"33","author":"Arnette","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"issue":"23","key":"10.1016\/j.hoc.2020.08.010_bib116","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib117","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1078-0432.CCR-0424-03","article-title":"Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells","volume":"10","author":"Ulmer","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM200302063480620","article-title":"Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery","volume":"348","author":"MacKie","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib119","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(10)70024-3","article-title":"Transmission of donor melanoma by organ transplantation","volume":"11","author":"Strauss","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2020.08.010_bib120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10585-018-9893-y","article-title":"Genetics of metastasis: melanoma and other cancers","volume":"35","author":"Turner","year":"2018","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib121","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","article-title":"Punctuated evolution of canonical genomic aberrations in uveal melanoma","volume":"9","author":"Field","year":"2018","journal-title":"Nat Commun"},{"issue":"6009","key":"10.1016\/j.hoc.2020.08.010_bib122","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib123","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.cell.2006.06.008","article-title":"Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene","volume":"125","author":"Kim","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib124","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/pcmr.12771","article-title":"Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities","volume":"32","author":"Eroglu","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib125","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib126","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib127","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib128","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1755-148X.2008.00491.x","article-title":"Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival","volume":"21","author":"Cartlidge","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"issue":"16","key":"10.1016\/j.hoc.2020.08.010_bib129","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-07-0665","article-title":"Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1","volume":"13","author":"Wang","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib130","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.1038\/s41467-019-12477-y","article-title":"Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies","volume":"10","author":"Montero","year":"2019","journal-title":"Nat Commun"},{"issue":"6892","key":"10.1016\/j.hoc.2020.08.010_bib131","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib132","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2020.08.010_bib133","first-page":"5198","article-title":"Suppression of BRAF(V599E) in human melanoma abrogates transformation","volume":"63","author":"Hingorani","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib134","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jid.2013.338","article-title":"The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in\u00a0situ of lentigo maligna type","volume":"134","author":"Stadelmeyer","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib135","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.hoc.2020.08.010_bib136","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-13-1746","article-title":"BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition","volume":"19","author":"Hutchinson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib137","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41388-018-0514-7","article-title":"BRAF fusions identified in melanomas have variable treatment responses and phenotypes","volume":"38","author":"Turner","year":"2019","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib138","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Palanisamy","year":"2010","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.08.010_bib139","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.hoc.2020.08.010_bib140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib141","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib142","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib143","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib144","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/2159-8290.CD-14-0856","article-title":"PI3'-kinase inhibition forestalls the onset of MEK1\/2 inhibitor resistance in BRAF-mutated melanoma","volume":"5","author":"Deuker","year":"2015","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib146","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/nm.2941","article-title":"Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma","volume":"18","author":"Kwong","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib147","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/2159-8290.CD-18-0224","article-title":"Dual MAPK\/CDK targeting in melanoma: new approaches, new challenges","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib148","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cell.2019.01.002","article-title":"Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis","volume":"176","author":"Yin","year":"2019","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib149","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.3361","article-title":"Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas","volume":"47","author":"Krauthammer","year":"2015","journal-title":"Nat Genet"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib150","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib151","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1158\/2159-8290.CD-18-0879","article-title":"MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas","volume":"9","author":"Maertens","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib152","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ccell.2014.11.014","article-title":"mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation","volume":"27","author":"Damsky","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib153","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-17-0699","article-title":"In In\u00a0Vivo E2F reporting reveals efficacious schedules of MEK1\/2-CDK4\/6 Targeting and mTOR-S6 Resistance Mechanisms","volume":"8","author":"Teh","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib154","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0048-9697(97)00297-0","article-title":"Significance and utility of reference values in occupational medicine","volume":"209","author":"Apostoli","year":"1998","journal-title":"Sci Total Environ"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib156","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.jid.5700026","article-title":"Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma","volume":"126","author":"Goel","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib157","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J\u00a0Invest Dermatol"},{"issue":"13","key":"10.1016\/j.hoc.2020.08.010_bib158","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib159","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1172\/JCI69619","article-title":"Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma","volume":"123","author":"Marsh Durban","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib160","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0092-8674(95)90370-4","article-title":"Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia","volume":"81","author":"Nobes","year":"1995","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib161","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ng.2359","article-title":"Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma","volume":"44","author":"Krauthammer","year":"2012","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib162","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A\u00a0landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"issue":"7399","key":"10.1016\/j.hoc.2020.08.010_bib163","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature11071","article-title":"Melanoma genome sequencing reveals frequent PREX2 mutations","volume":"485","author":"Berger","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib164","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2019.05.015","article-title":"RAC1(P29S) induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance","volume":"36","author":"Lionarons","year":"2019","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib165","doi-asserted-by":"crossref","first-page":"E1296","DOI":"10.1073\/pnas.1513801113","article-title":"Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma","volume":"113","author":"Lissanu Deribe","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"10.1016\/j.hoc.2020.08.010_bib166","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","article-title":"The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF","volume":"74","author":"Watson","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib167","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ccell.2018.05.014","article-title":"Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation","volume":"34","author":"Zeng","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib168","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1158\/2159-8290.CD-15-0196","article-title":"CDKN2B loss promotes progression from benign melanocytic nevus to melanoma","volume":"5","author":"McNeal","year":"2015","journal-title":"Cancer Discov"},{"issue":"6278","key":"10.1016\/j.hoc.2020.08.010_bib169","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"6122","key":"10.1016\/j.hoc.2020.08.010_bib171","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"issue":"7653","key":"10.1016\/j.hoc.2020.08.010_bib172","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2020.08.010_bib173","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1038\/ncomms4401","article-title":"Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma","volume":"5","author":"Heidenreich","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib174","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12441","article-title":"TERT promoter mutations associate with fast-growing melanoma","volume":"29","author":"Nagore","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040452","article-title":"TERT promoter mutations are associated with visceral spreading in melanoma of the trunk","volume":"11","author":"Osella-Abate","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.hoc.2020.08.010_bib176","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"20","key":"10.1016\/j.hoc.2020.08.010_bib177","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1158\/1078-0432.CCR-17-0980","article-title":"MAPK Pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases","volume":"23","author":"Bai","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2020.08.010_bib178","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6664","key":"10.1016\/j.hoc.2020.08.010_bib179","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/34681","article-title":"MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes","volume":"391","author":"Hemesath","year":"1998","journal-title":"Nature"},{"issue":"7229","key":"10.1016\/j.hoc.2020.08.010_bib180","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.hoc.2020.08.010_bib181","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib182","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib183","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib184","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib185","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.cell.2012.07.033","article-title":"Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma","volume":"150","author":"Lian","year":"2012","journal-title":"Cell"},{"issue":"7339","key":"10.1016\/j.hoc.2020.08.010_bib186","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nature09806","article-title":"The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset","volume":"471","author":"Ceol","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib187","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1158\/2159-8290.CD-19-0532","article-title":"Gain-of-function genetic alterations of G9a drive oncogenesis","volume":"10","author":"Kato","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib188","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.3779","article-title":"SWI\/SNF complex in cancer","volume":"49","author":"Lu","year":"2017","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib189","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib190","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-13-3608","article-title":"SWI\/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability","volume":"74","author":"Watanabe","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib191","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","article-title":"The SWI\/SNF complex in cancer - biology, biomarkers and therapy","volume":"17","author":"Mittal","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib192","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2020.08.010_bib193","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib194","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib196","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/pcmr.12674","article-title":"BRAF internal deletions and resistance to BRAF\/MEK inhibitor therapy","volume":"31","author":"Johnson","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.hoc.2020.08.010_bib197","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance","volume":"3","author":"Shi","year":"2012","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib198","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"7377","key":"10.1016\/j.hoc.2020.08.010_bib199","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib200","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.08.010_bib201","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib202","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"issue":"7674","key":"10.1016\/j.hoc.2020.08.010_bib203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"issue":"7478","key":"10.1016\/j.hoc.2020.08.010_bib204","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","article-title":"A\u00a0melanocyte lineage program confers resistance to MAP kinase pathway inhibition","volume":"504","author":"Johannessen","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"issue":"6282","key":"10.1016\/j.hoc.2020.08.010_bib206","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.hoc.2020.08.010_bib207","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib208","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In In\u00a0vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib209","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","article-title":"Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature","volume":"19","author":"Hoek","year":"2006","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.hoc.2020.08.010_bib210","doi-asserted-by":"crossref","first-page":"6683","DOI":"10.1038\/ncomms7683","article-title":"Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state","volume":"6","author":"Verfaillie","year":"2015","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.hoc.2020.08.010_bib211","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A\u00a0melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.08.010_bib212","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib213","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/jid.2011.218","article-title":"Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase","volume":"131","author":"Sensi","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"22","key":"10.1016\/j.hoc.2020.08.010_bib214","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1158\/1078-0432.CCR-17-0010","article-title":"MITF-High and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra- and intertumoral heterogeneity of primary melanoma","volume":"23","author":"Ennen","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2020.08.010_bib215","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","article-title":"Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation","volume":"7","author":"Song","year":"2017","journal-title":"Cancer Discov"},{"issue":"52","key":"10.1016\/j.hoc.2020.08.010_bib216","doi-asserted-by":"crossref","first-page":"13679","DOI":"10.1073\/pnas.1712064115","article-title":"Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance","volume":"114","author":"Su","year":"2017","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib217","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib218","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib219","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20160855","article-title":"An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition","volume":"214","author":"Young","year":"2017","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2020.08.010_bib220","doi-asserted-by":"crossref","first-page":"8755","DOI":"10.1038\/ncomms9755","article-title":"MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment","volume":"6","author":"Riesenberg","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.hoc.2020.08.010_bib221","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF\u03b1","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.08.010_bib222","doi-asserted-by":"crossref","first-page":"14343","DOI":"10.1038\/ncomms14343","article-title":"Microenvironment-derived factors driving metastatic plasticity in melanoma","volume":"8","author":"Kim","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib223","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.stem.2017.08.003","article-title":"Mouse cutaneous melanoma induced by mutant braf arises from expansion and dedifferentiation of mature pigmented melanocytes","volume":"21","author":"Kohler","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib224","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","article-title":"An acquired vulnerability of drug-resistant melanoma with therapeutic potential","volume":"173","author":"Wang","year":"2018","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.hoc.2020.08.010_bib225","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib226","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib227","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.hoc.2020.08.010_bib228","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib229","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.08.010_bib230","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2020.08.010_bib231","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib232","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41591-020-0818-3","article-title":"Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy","volume":"26","author":"Perez-Guijarro","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib233","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","article-title":"Immunotherapy resistance by inflammation-induced dedifferentiation","volume":"8","author":"Mehta","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib234","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib235","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","article-title":"A\u00a0cancer cell program promotes T\u00a0cell exclusion and resistance to checkpoint blockade","volume":"175","author":"Jerby-Arnon","year":"2018","journal-title":"Cell"},{"issue":"6377","key":"10.1016\/j.hoc.2020.08.010_bib236","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A\u00a0major chromatin regulator determines resistance of tumor cells to T\u00a0cell-mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib237","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib238","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.hoc.2020.08.010_bib239","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1172\/JCI134402","article-title":"Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.hoc.2020.08.010_bib240","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.18632\/oncotarget.6494","article-title":"Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy","volume":"7","author":"Goh","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.hoc.2020.08.010_bib241","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/modpathol.2013.235","article-title":"Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma","volume":"27","author":"Cimino","year":"2014","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2020.08.010_bib242","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.hoc.2020.08.010_bib243","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1038\/s41467-018-06027-1","article-title":"The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature","volume":"9","author":"Inman","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.hoc.2020.08.010_bib244","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic data","volume":"375","author":"Grossman","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:16:09Z","timestamp":1760184969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":244,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0889858820301088"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.08.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biology of Melanoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}